Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

International Stem Cell (ISCO) EPS (Weighted Average and Diluted) (2016 - 2025)

International Stem Cell (ISCO) has disclosed EPS (Weighted Average and Diluted) for 13 consecutive years, with $0.01 as the latest value for Q2 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 13.69% to $0.01 in Q2 2025 year-over-year; TTM through Sep 2025 was -$0.01, a 76.53% increase, with the full-year FY2024 number at -$0.03, down 50.0% from a year prior.
  • EPS (Weighted Average and Diluted) was $0.01 for Q2 2025 at International Stem Cell, up from -$0.03 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.03 in Q2 2023 to a low of -$0.06 in Q2 2021.
  • A 5-year average of -$0.01 and a median of -$0.01 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 12106.0% in 2023; the steepest drop was 957.61% in 2023.
  • International Stem Cell's EPS (Weighted Average and Diluted) stood at -$0.04 in 2021, then surged by 108.75% to $0.0 in 2022, then crashed by 957.61% to -$0.03 in 2023, then soared by 105.0% to $0.0 in 2024, then skyrocketed by 658.33% to $0.01 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's EPS (Weighted Average and Diluted) are $0.01 (Q2 2025), -$0.03 (Q1 2025), and $0.0 (Q4 2024).